Publications by authors named "David Moskal"
Background: Surgeons rarely perform elective total pancreatectomy (TP). Our study seeks to report surgical outcomes in a contemporary series of single-stage (SS) TP patients.
Methods: Between the years 2013 to 2023 we conducted a retrospective review of 60 consecutive patients who underwent SSTP.
Article Synopsis
- - The study aimed to create an opioid reduction toolkit to decrease narcotic prescriptions and increase awareness of safe disposal among patients who underwent pancreatectomy surgery.
- - Data from 159 patients showed a significant reduction in both the amount of opioids prescribed (from 225 MMEs to 75 MMEs) and consumed (from 109 MMEs to 15 MMEs) post-toolkit implementation, with no change in refill request rates.
- - Patient awareness of safe disposal practices for unused opioids significantly improved, rising from 25% before the toolkit to 62% after its introduction.
Background And Objective: Robotic distal pancreatectomy (DP) is an emerging attractive approach, but its role compared with laparoscopic or open surgery remains unclear. Benchmark values are novel and objective tools for such comparisons. The aim of this study was to identify benchmark cutoffs for many outcome parameters for DP with or without splenectomy beyond the learning curve.
View Article and Find Full Text PDFPurpose: Sarcopenia is common in pancreatic cancer patients. Considering the growing adoption of standardized protocols for enhanced recovery after surgery (ERAS), we examined the clinical impact of sarcopenia in pancreaticoduodenectomy (PD) patients in a 5-day accelerated ERAS program, termed the Whipple Accelerated Recovery Pathway.
Methods: A retrospective review was conducted of patients undergoing PD from 2017 through 2020 on the ERAS pathway.
Background: Next-generation sequencing (NGS) provides information on genetic mutations and mutant allele frequency in tumor specimens. We investigated the prognostic significance of KRAS mutant allele frequency in patients with right-sided pancreatic ductal adenocarcinoma (PDAC) treated with surgical resection.
Methods: A retrospective study reviewed patients who underwent surgical resection for PDAC and analyzed tumors with an in-house mutational panel.
The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis.
Ann Surg
November 2021
Article Synopsis
- The study aimed to determine the impact of neoadjuvant therapy (NAT) on the rates of complete tumor resection (R0) and long-term survival outcomes in patients with pancreatic ductal adenocarcinoma undergoing surgery with vein resection.
- Overall, results from 1192 patients showed that those who received NAT had significantly higher rates of R0 resection (57%) and better survival rates after 1, 3, and 5 years compared to those who did not receive NAT.
- The findings suggest that NAT should be considered routinely for patients with pancreatic ductal adenocarcinoma scheduled for surgery involving venous reconstruction.
Objective: The aim of this study was to establish clinically relevant outcome benchmark values using criteria for pancreatoduodenectomy (PD) with portomesenteric venous resection (PVR) from a low-risk cohort managed in high-volume centers.
Summary Background Data: PD with PVR is regarded as the standard of care in patients with cancer involvement of the portomesenteric venous axis. There are, however, no benchmark outcome indicators for this population which hampers comparisons of patients undergoing PD with and without PVR resection.
Objective: The 30-day readmission rate is of increasing interest to hospital administrators and physicians, as it is used to evaluate hospital performance and is associated with increased healthcare expenditures. The estimated yearly cost to Medicare of readmissions is $17.4 billion.
View Article and Find Full Text PDF